1. Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer 
Rafael Gadia, MD, Elton Trigo Teixeira Leite, MD, Ana Luiza Bierrenbach, PhD, Fabio Ynoe de Moraes, MD, Daniel E. Spratt, MD, Fernando Freire Arruda, MD, Carlos Eduardo Cintra Vita Abreu, MD, Joao Luis Fernandes da Silva, MD, Heloisa de Andrade Carvalho, PhD, Bernardo Garicochea, PhD 
Advances in Radiation Oncology 
Volume 1, Issue 4, Pages (October 2016)
DOI: /j.adro
Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

2. Figure 1
Kaplan-Meier curves for biochemical failure by relevant risk factors: Nadir prostate-specific antigen levels (A) and risk classification (B).
Advances in Radiation Oncology 2016 1, DOI: ( /j.adro )
Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

3. Figure 2
Kaplan-Meier curves for distant metastases by relevant risk factors: prostate-specific antigen nadir levels (A), risk classification (B), perineural invasion (C), and biochemical failure (D).
Advances in Radiation Oncology 2016 1, DOI: ( /j.adro )
Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

4. Figure 3
Kaplan-Meier curves for deaths due to all causes by relevant risk factors: age (A), metastases (B), risk classification (C), and biochemical failure (D).
Advances in Radiation Oncology 2016 1, DOI: ( /j.adro )
Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

5. Figure 4
Kaplan-Meier curves for deaths due to prostate cancer by relevant risk factors: age (A), metastases (B), risk classification (C), and biochemical failure (D).
Advances in Radiation Oncology 2016 1, DOI: ( /j.adro )
Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions